Raj Indupuri

Contributor   in
Emerging Technologies  

Raj Indupuri is the CEO of eClinical Solutions and is passionate about introducing and implementing solutions and technologies to further clinical research development. With a unique blend of hands-on technical and data management experience, Raj works to advance the eClinical Solutions strategic vision and the delivery of cloud-based solutions.

tags:   Artificial Intelligence     coronavirus    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Clinical Research, Artificial Intelligence, and COVID-19

Clinical Research, Artificial Intelligence, and COVID-19

How life sciences companies are reimagining trials during the biggest health crisis in a century

Whatever the world was like on March 15, it’s not like that now — and it probably won’t be for months or years. Everything from buying groceries to renewing a driver’s license is completely different from the way we did things just a few months ago. Clinical trials, like most medical activities, have been significantly affected as governments and pharmaceutical companies have pivoted to a single focus: combatting the novel coronavirus. At the same time, the rush to develop cures and vaccines for COVID-19 is condensing the review and approval process from years to months. This is where artificial intelligence (AI) can play a vital role in changing how clinical trials are conducted and how therapies are evaluated and tested.